The ArteraAI Prostate Test Enhanced with New Insights for Higher Risk Patients with Localized Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predi [...]
Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care
Oral presentation selected for Best of ASCO 2025 in recognition of quality, rigor, and impact First validated algorithm to id [...]
Diagnexia and Artera Partner to Bring Groundbreaking AI Prostate Test to the UK
Diagnexia, the UK’s leading provider of AI-powered digital pathology diagnostic services, is thrilled to announce an exclusiv [...]
Phase 3 trial launches of ArteraAI Prostate test for treatment selection
Clinical trial aims to guide doctors in selecting the most effective treatments that minimize the impact on quality of life w [...]
Tempus Partners with Artera to Expand Personalized Prostate Cancer Treatment
Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S. SAN FRANCISCO--(BUSINESS WIRE)--Artera, th [...]
Artera’s Multimodal Artificial Intelligence Named Among TIME’s 2024 Best Inventions
The prestigious recognition highlights Artera’s innovation and impact in advancing the personalization of prostate cancer tre [...]
Artera Receives California Lab License, Expanding Access to its ArteraAI Prostate Test
Clinicians and patients in California can now access personalized, actionable insights to inform prostate cancer treatment de [...]
Artera Announces Two Presentations at ASTRO 2024 Validating its MMAI Platform to Inform Treatment Decisions for Oligometastatic Castration-Sensitive Prostate Cancer (omCSPC)
Data demonstrates the multimodal artificial intelligence (MMAI) biomarker’s ability to prognosticate and predict the therapeu [...]
Artera Announces Expansion of the ArteraAI Prostate Test to Inform Active Surveillance Decisions for Lower Risk Prostate Cancer Patients
The test report now provides personalized insights for prostate cancer patients considering active surveillance SAN FRANCISCO [...]